_version_ 1784786259770605568
author Glasberg, João
Talans, Aley
Giollo, Thomás Rivelli
Recchimuzzi, Débora Zachello
Neto, João Evangelista Bezerra
Lopez, Rossana Veronica Mendonza
Hoff, Paulo Marcelo Gehm
Riechelmann, Rachel P
author_facet Glasberg, João
Talans, Aley
Giollo, Thomás Rivelli
Recchimuzzi, Débora Zachello
Neto, João Evangelista Bezerra
Lopez, Rossana Veronica Mendonza
Hoff, Paulo Marcelo Gehm
Riechelmann, Rachel P
author_sort Glasberg, João
collection PubMed
description
format Online
Article
Text
id pubmed-9458264
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-94582642022-09-23 METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours Glasberg, João Talans, Aley Giollo, Thomás Rivelli Recchimuzzi, Débora Zachello Neto, João Evangelista Bezerra Lopez, Rossana Veronica Mendonza Hoff, Paulo Marcelo Gehm Riechelmann, Rachel P Ecancermedicalscience Erratum Cancer Intelligence 2022-07-04 /pmc/articles/PMC9458264/ /pubmed/36158978 http://dx.doi.org/10.3332/ecancer.2022.1421 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Erratum
Glasberg, João
Talans, Aley
Giollo, Thomás Rivelli
Recchimuzzi, Débora Zachello
Neto, João Evangelista Bezerra
Lopez, Rossana Veronica Mendonza
Hoff, Paulo Marcelo Gehm
Riechelmann, Rachel P
METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title_full METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title_fullStr METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title_full_unstemmed METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title_short METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
title_sort metnet: a phase ii trial of metformin in patients with well-differentiated neuroendocrine tumours
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458264/
https://www.ncbi.nlm.nih.gov/pubmed/36158978
http://dx.doi.org/10.3332/ecancer.2022.1421
work_keys_str_mv AT glasbergjoao metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT talansaley metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT giollothomasrivelli metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT recchimuzzideborazachello metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT netojoaoevangelistabezerra metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT lopezrossanaveronicamendonza metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT hoffpaulomarcelogehm metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours
AT riechelmannrachelp metnetaphaseiitrialofmetformininpatientswithwelldifferentiatedneuroendocrinetumours